{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:36:17Z","timestamp":1791196577347,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ctrv.2015.04.003","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T07:51:28Z","timestamp":1428738688000},"page":"58-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies"],"prefix":"10.1016","volume":"43","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2015.04.003_b0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.2007-0228","article-title":"Battling the hematological malignancies: the 200 years\u2019 war","volume":"13","author":"Lichtman","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2015.04.003_b0010","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/annonc\/mdn792","article-title":"HDAC inhibitor-based therapies and haematological malignancy","volume":"20","author":"Stimson","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0015","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0020","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2010.531409","article-title":"Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)","volume":"52","author":"Venner","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2015.04.003_b0030","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.04.003_b0035","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.04.003_b0040","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.04.003_b0045","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.25218","article-title":"Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance","volume":"127","author":"Shao","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2015.04.003_b0050","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ctrv.2015.04.003_b0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: clinical update and mechanism-based potential","volume":"74","author":"Glaser","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0060","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.leukres.2010.04.001","article-title":"Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed\/refractory multiple myeloma","volume":"34","author":"Jagannath","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2015.04.003_b0065","unstructured":"ZOLINZA (vorinostat) [prescribing information]. Merck & Co., Inc. Whitehouse Station, NJ, USA, 2011."},{"key":"10.1016\/j.ctrv.2015.04.003_b0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ctrv.2015.04.003_b0080","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 15","key":"10.1016\/j.ctrv.2015.04.003_b0085","doi-asserted-by":"crossref","first-page":"e18504","DOI":"10.1200\/jco.2010.28.15_suppl.e18504","article-title":"Carfilzomib (CFZ) in combination with DEX and other agents (Dox, Thal, DDP, vorinostat) for far advanced and refractory multiple myeloma (FARMM)","volume":"28","author":"Alsayed","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0090","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0100","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0105","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.ctrv.2015.04.003_b0110","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood.V116.21.3065.3065","article-title":"Vorinostat overcomes lenalidomide\u2013dexamethasone and lenalidomide\u2013bortezomib\u2013dexamethasone resistance in relapsed\/refractory multiple myeloma","volume":"116","author":"Siegel","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2015.04.003_b0115","first-page":"119","article-title":"VANTAGE 095: Final results from a global, single-arm phase 2b trial of vorinstat in combination with bortezomib in salvage multiple myeloma patients","volume":"97","author":"Siegel","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2015.04.003_b0120","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1038\/bcj.2014.23","article-title":"Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"4","author":"Siegel","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2015.04.003_b0125","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V116.21.1955.1955","article-title":"Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed\/refractory multiple myeloma","author":"Voorhees","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","article-title":"Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma","volume":"101","author":"Watanabe","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2015.04.003_b0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2012.07.007","article-title":"Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and\/or refractory multiple myeloma","volume":"12","author":"Weber","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2015.04.003_b0140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0145","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1158\/1078-0432.CCR-09-1214","article-title":"A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer","volume":"15","author":"Munster","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.04.003_b0150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5603\/CJ.2012.0078","article-title":"QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature","volume":"19","author":"Lynch","year":"2012","journal-title":"Cardiol J"},{"key":"10.1016\/j.ctrv.2015.04.003_b0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-011-1240-1","article-title":"Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)","volume":"91","author":"Cashen","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0160","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.04.003_b0165","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","article-title":"Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia","volume":"112","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2015.04.003_b0170","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood.V112.11.5084.5084","article-title":"A randomized phase IIa study of vorinostat in patients with low or intermediate-1 risk myelodysplatic syndromes: preliminary results","volume":"112","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0175","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0180","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1158\/1078-0432.CCR-06-1802","article-title":"A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer","volume":"12","author":"Rubin","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.04.003_b0185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0190","unstructured":"M. Ogura, K. Ando, K. Tobinai et al. A phase I study of vorinostat combined with bortezomib in patients with relapsed or refractory multiple myeloma. Annual Meeting of the Japanese Society of Hematology 2013; Sapporo City, Japan."},{"key":"10.1016\/j.ctrv.2015.04.003_b0195","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","article-title":"Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy","volume":"16","author":"Wright","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.04.003_b0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.seminhematol.2009.02.003","article-title":"Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib","volume":"46","author":"Mitsiades","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.12230","article-title":"A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma","volume":"161","author":"Budde","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0210","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2015.04.003_b0215","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0220","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bjh.12326","article-title":"Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma","volume":"162","author":"Oki","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000286447","article-title":"The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide","volume":"33","author":"Schmitt","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.ctrv.2015.04.003_b0230","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","article-title":"Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma","volume":"53","author":"Wolf","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2015.04.003_b0235","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0240","unstructured":"ISTODAX\u00ae (romidepsin) [prescribing information]. Celgene. Summit, NJ, USA, 2012."},{"key":"10.1016\/j.ctrv.2015.04.003_b0245","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0250","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0255","doi-asserted-by":"crossref","unstructured":"F. Child, P.O. Romero, R. Alvarez et al. Phase 2 multicenter trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously teated stage IB-IVA cutaneous T-cell lymphoma, 2012; 3676.","DOI":"10.1182\/blood.V120.21.3676.3676"},{"key":"10.1016\/j.ctrv.2015.04.003_b0260","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","article-title":"A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0265","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3109\/10428194.2012.664844","article-title":"Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed\/refractory multiple myeloma","volume":"53","author":"Offidani","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.ctrv.2015.04.003_b0270","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V118.21.814.814","article-title":"Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2)","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0275","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","article-title":"Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2015.04.003_b0280","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood.V108.11.3583.3583","article-title":"A phase II study of PXD101 in advanced multiple myeloma","volume":"108","author":"Sullivan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0285","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0290","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2010.262","article-title":"Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes","volume":"25","author":"Giver","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2015.04.003_b0295","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.exphem.2012.02.004","article-title":"Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation","volume":"40","author":"Iancu-Rubin","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0300","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.04.003_b0305","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10637-006-9017-4","article-title":"Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors","volume":"25","author":"Camacho","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2015.04.003_b0310","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.04.003_b0315","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10637-008-9190-8","article-title":"Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)","volume":"27","author":"Whitehead","year":"2009","journal-title":"Invest New Drugs"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T15:50:53Z","timestamp":1598889053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":63,"alternative-id":["S0305737215000729"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.04.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}